Original Article
Prenatal Care, Pregnancy Outcomes, and Postpartum Birth Control Plans Among Pregnant Women with Opiate Addictions
Abstract
Objectives: To describe how effectively we provided adequate prenatal care and postpartum contraception to prevent repeat, unintended pregnancies to women using opiates or medication maintenance therapy (MMT) during pregnancy.Methods: We conducted a retrospective chart review of 94 women using opiates or MMT during 96 pregnancies while receiving prenatal care in the regional high-risk maternity care clinic between July 2010 and June 2012. We examined prenatal care usage, birth outcomes, and postpartum contraception using χ2 , Kruskal-Wallis, and binary logistic regression modeling.
Results: Patients were predominately white (93.6%), multiparous (75.5%), and in their 20s; 71 (74%) used MMT and 25 (26%) used prescribed or illicit opiates. Fewer than half (44% [46.2%]) received any documented prenatal counseling about postpartum contraception. Sixteen (17%) babies were premature. Sixty-four (66.7%) infants were diagnosed as having neonatal abstinence syndrome (NAS). Only 42 (43.8%) women attended their postpartum visits. Overall, 60 (62.5%) women received postpartum contraception. The only significant predictors of postpartum contraception use were preterm birth and postpartum appointment attendance.
Conclusions: Alternative strategies for providing postpartum care should be explored because women using opiates or MMT during pregnancy are significantly more likely to use postpartum contraception if they attend their postpartum appointments.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.
References
1. Patrick SW, Schumacher RE, Benneyworth BD, et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009. JAMA 2012;307:1934-1940.
2. Logan BA, Brown MS, Hayes MJ. Neonatal abstinence syndrome: treatment and pediatric outcomes. Clin Obstet Gynecol 2013;56:186-192.
3. ACOG Committee on Health Care for Underserved Women; American Society of Addiction Medicine. ACOG Committee Opinion No. 524: opioid abuse, dependence, and addiction in pregnancy. Obstet Gynecol 2012;119:1070-1076.
4. Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol 2006;126:170-175.
5. Dryden D, Young D, Hepburn M, et al. Maternal methadone use in pregnancy: factors associated with the development of neonatal abstinence syndrome and implications for healthcare resources. BJOG 2009;116:665-671.
6. Pritham UA, Paul JA, Hayes MJ. Opioid dependency in pregnancy and length of stay for neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 2012;41:180-190.
7. Finnegan LP, Hagan T, Kaltenbach KA. Scientific foundation of clinical practice: opiate use in pregnant women. Bull N Y Acad Med 1991;67:223-239.
8. Osborn DA, Jeffery HE, Cole MJ. Opiate treatment for opiate withdrawal in newborn infants. Cochrane Database Syst Rev 2010;10:CD002059.
9. Velez M, Jansson LM. The opioid dependent mother and newborn dyad:non-pharmacologic care. J Addict Med 2008;2:113-120.
10. Seligman NS, Almario CV, Hayes EJ, et al. Relationship between maternal methadone dose at delivery and neonatal abstinence syndrome. J Pediatr 2010;157:428-433.
11. Seligman NS, Salva N, Hayes EJ, et al. Predicting length of treatment for neonatal abstinence syndrome in methadone-exposed neonates. Am J Obstet Gynecol 2008;199:396.e1-396.e7.
12. Ordean A, Kahan M. Comprehensive treatment program for pregnant substance users in a family medicine clinic. Can Fam Physician 2011;57:e430-e435.
13. Kukko H, Halmesmaki E. Prenatal care and counseling of female drug-abusers: effects of drug abuse and perinatal outcome. Acta Obstet Bynecol Scand 1999;78:22-26.
14. Phillips D, Thomas K, Cox H. Factors that influence women’s disclosures of substance use during pregnancy: a qualitative study of ten midwives and ten pregnant women. J Drug Issues 2007;2:357-376.
15. Clark KA, Dee DL, Bale PL, et al. Treatment compliance among prenatal care patients with substance abuse problems. Am J Drug Alcohol Abuse 2001;27:121-136.
16. Schempf AH, Strobino DM. Drug use and limited prenatal care: an examination of responsible barriers. Am J Obstet Gynecol 2009;200:412e1-412e10.
17. Brady TM, Visscher W, Feder M, et al. Maternal drug use and the timing of prenatal care. J Health Care Poor Underserved 2003;14:588-607.
18. Goldenberg RL, Patterson ET, Freese MP. Maternal demographic, situational and psychosocial factors and their relationship to enrollment in prenatal care: a review of the literature. Women Health 1992;19:133-151.
19. Harvey SM, Faber KS. Obstacles to prenatal care following implementation of a community-based program to reduce financial barriers. Fam Plann Perspect 1993;25:32-36.
20. Heil SH, Jones HE, Arria A, et al. Unintended pregnancy in opioid-abusing women. J Subst Abuse Treat 2011;40:199-202.
21. Mosher WD, Jones J, Abma JC. Intended and unintended births in the United States: 1982-2010. http://www.cdc.gov/nchs/data/nhsr/nhsr055.pdf. Published 2012. Accessed January 3, 2014.
22. Black KI, Stephens C, Haber PS, et al. Unplanned pregnancy and contraceptive use in women attending drug treatment services. Aust N Z J Obstet Gynaecol 2012;52:146-150.
23. Cleary BJ, Eogan M, O’Connell MP, et al. Methadone and perinatal outcomes: a prospective cohort study. Addiction 2012;107:1482-1492.
24. Ebner N, Rohrmeister K, Winklbaur B, et al. Management of neonatal abstinence syndrome in neonates born to opioid maintained women. Drug Alcohol Depend 2007;87:131-138.
25. Funai EF, White J, Lee MJ, et al. Compliance with prenatal care visits in substance abusers. J Matern Fetal Neonatal Med 2003;14:329-332.
26. Standards for Obstetric-Gynecologic Services. 6th ed. Washington, DC: American College of Obstetricians and Gynecologists; 1985.
27. Hernandez LE, Sappenfield WM, Goodman D, et al. Is effective contraceptive use conceived prenatally in Florida? The association between prenatal contraceptive counseling and postpartum contraceptive use. Matern Child Health J 2012;16:423-429.
28. Jones J, Mosher WD, Daniels K. Current contraceptive use in the United States, 2006-2010, and changes in patterns of use since 1995. http://www.cdc.gov/nchs/data/nhsr/nhsr060.pdf. Published October 18, 2012. Accessed April 4, 2014.
29. Morrison CL, Reuben SM, Beeching NJ. Female sexual health problems in a drug dependency unit. Int J STD AIDS 1995;6:201-203.
30. Guttmacher Institute. Fact sheet: contraceptive use in the United States. http://www.guttmacher.org/pubs/fb_contr_use.html#9. Published June 2014. Accessed September 18, 2014.
31. Sinha C, Guthrie KA, Lindow SW. A survey of postnatal contraception in opiate-using women. J Fam Plann Reprod Health Care 2007;33:31-34.
32. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; Long-Acting Reversible Contraception Working Group. ACOG Committee Opinion no. 450: increasing use of contraceptive implants and intrauterine devices to reduce unintended pregnancy. Obstet Gynecol 2009;114:1434-1438.
33. Dempsey AR, Billingsley CC, Savage AH, et al. Predictors of long-acting reversible contraception use among unmarried young adults. Am J Obstet Gynecol 2012;206:526.e1-e5.
34. Peipert JF, Madden T, Allsworth JE, et al. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol 2012;120:1291-1297.
35. RamaRao S, Lacuesta M, Costello M, et al. The link between quality of care and contraceptive use. Int Fam Plann Perspect 2003;29:76-83.
36. Berenson AB, Wiemann CM. Contraceptive use among adolescent mothers at 6 months postpartum. Obstet Gynecol 1997;89:999-1005.
37. Centering Healthcare Institute. Centering pregnancy overview. http://www.centeringhealthcare.org/pages/centering-model/pregnancy-overview.php. Published 2014. Accessed June 30, 2014.
38. Hale N, Picklesimer AH, Billings DL, et al. The impact of Centering Pregnancy Group prenatal care on postpartum family planning. Am J Obstet Gynecol 2014;210:50.e1-50.e7.
39. Niccols A, Milligan K, Sword W, et al. Maternal mental health and integrated programs for mothers with substance abuse issues. Psychol Addict Behav 2010;24:466-474.
40. Sweeney PJ, Schwartz RM, Mattis NG, et al. The effect of integrating substance abuse treatment with prenatal care on birth outcome. J Perinatol 2000;20:219-224.
41. Ordean A, Kahan M. Comprehensive treatment program for pregnant substance users in a family medicine clinic. Can Fam Physician 2011;57:e430-e435.
42. Jansson LM, Svikis D, Lee J, et al. Pregnancy and addiction: a comprehensive care model. J Subst Abuse Treat 1996;13:321-329.
43. Tocce KM, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol 2012;206:481.e1-481.e7.
44. Health Management Associates. Medicaid reimbursement for immediate post-partum LARC. https://www.acog.org/~/media/Departments/LARC/HMAPostpartumReimbursmentResource.pdf. Published May 2013. Accessed June 30, 2014.
45. Issel LM. Women’s perceptions of outcomes of prenatal case management. Birth 2000;27:120-126.
46. Sangalang BB, Barth RP, Painter JS. First-birth outcomes and timing of second births: a statewide case management program for adolescent mothers. Health Soc Work 2006;31:54-63.
